Novartis’ Kisqali Hits Mark in Mid-Stage Breast Cancer Trial

[cafead]

via Novartis' Kisqali, combined with endocrine therapy, offered almost a year of progression-free survival (PFS) for an aggressive form of HER+/HER2- metastatic breast cancer, the company announced Tuesday.

article source